Role of HbA 1C in diabetes mellitus

Journal, Indian Academy of Clinical Medicine

Volumn 10, Issue 1-2, 2009, Pages 52-54

  Thakur, S ^a   Chauhan, V ^a   Negi, R C ^a  

^a INDIRA GANDHI MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

ADULT; BLOOD GLUCOSE MONITORING; CASE REPORT; DIABETES EDUCATION; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INDIA; MORBIDITY; MORTALITY; REVIEW;

EID: 67749103699     PISSN: 09723560     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Rahbar S, Blemenfeld O, Ranney Har. Studies of an unusual haemoglobin in patients with diabetes mellitus. Biochem Biophys Res Commun 1969; 36: 83-88
2. Mc Gill JB, Cole TG, Nowatzke W et al. Circulating 1, 5 anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycaemia; a US trial of the glycomark assay. Diabetes Care 2004; 27: 1859-1865 (Pubitemid 38989223)
3. 1C? An analysis of glycated haemoglobins by electrospray ionisation mass spectrometry. Clin Chem 1998; 49: 1951-1958
4. 1C, slow glycosylation of haemoglobin in vivo. J Clin Invest 1976; 57: 1652-1659
5. Goldstein DE, Little RR, Lorenz RA et al. Tests of glycaemia in diabetes. Diabetes Care 2004; 27: 1761-1773
6. Beach KW. A theoretical model to predict the behaviour of glycosylated haemoglobin levels. J Theor Biol 1979; 81: 547-561
7. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin and fructosamine and analysis of their weight functions against preceeding plasma glucose level. Diabetes Care 1995; 18: 440-447
8. Kulberg CE, Bergstrom A, Dinesen B et al. Comparisons of studies on diabetic complications hampered by differences in GHb measurements. Diabetes Care 1996; 19: 726-729 (Pubitemid 26255209)
9. Marshall SM, Home PD, Manley SE et al. Standardisation of glycated haemoglobin. Diabet Med 2002; 19: 429.
10. 1C in the diabetes control and complications trial. Diabetes Care 2002; 25: 275-278
11. 1C Assay in the estimated average glucose values. Diabetes Care 2008; 31: 1-6.
12. 1C in human blood. Clin Chem Lab Med 2002; 40: 78-79
13. Bry L, Chen PC, Sacks DB. Effects of haemoglobin variant and chemically modified derivatives on assays for glyco haemoglobin. Clin Chem 2001; 47: 155-163 (Pubitemid 32142912)
14. Davie SJ, Gould BJ, Yudkin JS. Effect of vit. C on glycosyalation of proteins. Diabetes 1992; 41: 167-173
15. Nielsen LR, Ekbom P, Damm P et al. HbA1c levels are significantly lower in early and late pregnancy. Diabetes Care 2004; 27: 1200-1201 (Pubitemid 38579790)
16. 1C in type I diabetes mellitus. Pediatr Int 1999; 41: 357-362
17. 1C affected by glycaemic instability? Diabetes Care 2003; 20: 2728-2733
18. Diabetes Control and Complications Research Trial Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986 (Pubitemid 23307905)
19. Nathan DM, Cleary PA, Blacklund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653 (Pubitemid 41817713)
20. UK prospective diabetes study (UKPDS) group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-853
21. Meigs JB, Nathan DM, D' Agostino RB Sr., Wilson PW. Framingham offspring study. Fasting and post challenge glycaemia and cardiovascular disease risk. Diabetes Care 2002; 25: 1845-1850
22. Strutton IM, Adler AL, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications in the type 2 diabetes (UKPDS35); Prospective observational study. BMJ 2000; 321: 405-412 (Pubitemid 30609442)
23. Selvin E, Marinopoul OS, Berkenblit G et al. Metaanalysis: Glycosylated haemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421-431 (Pubitemid 39281878)
24. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med 2008; 358: 2545-2559
25. Action in Diabetes and Vascular disease: preterAx and diamicroN modified release Controlled Evaluation study group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2008; 358: 2560-2572
26. Position statement American diabetic Association. Standards of Medical care in diabetes. Diabetes Care 2005; 28: S4-S36.